Telomir Competitors

Stocks . USA . 
Stock . Telomir Pharmaceuticals, Common
TELO Stock   1.40  0.03  2.10%   
Telomir Pharmaceuticals, competes with Medicus Pharma, Genenta Science, Century Therapeutics, Barinthus Biotherapeutics, and CEL SCI; as well as few others. The company conducts business under Pharmaceuticals sector and is part of Health Care industry. Analyzing Telomir Pharmaceuticals, competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Telomir Pharmaceuticals, to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Telomir Pharmaceuticals, Correlation with its peers.
You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Telomir Pharmaceuticals, competition on your existing holdings.
  
Build AI portfolio with Telomir Stock
Specify up to 10 symbols:
Hype
Prediction
LowEstimatedHigh
0.071.387.16
Details
Intrinsic
Valuation
LowRealHigh
0.244.8910.67
Details
Naive
Forecast
LowNextHigh
0.031.407.18
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
1.191.451.71
Details

Telomir Pharmaceuticals, Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Telomir Pharmaceuticals, and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Telomir and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Telomir Pharmaceuticals, does not affect the price movement of the other competitor.

High positive correlations

CVM
+ 0.88
BRNS
CVM
+ 0.8
MDCX
BRNS
+ 0.8
GNTA
CVM
+ 0.8
GNTA
EQ
+ 0.8
BRNS
BRNS
+ 0.78
MDCX
  

High negative correlations

IPSC
- 0.45
MDCX
CVM
- 0.36
IPSC
SKYE
- 0.3
IPSC
COEP
- 0.26
IPSC
KPTI
- 0.24
MDCX
IPSC
- 0.19
GNTA

Risk-Adjusted Indicators

There is a big difference between Telomir Stock performing well and Telomir Pharmaceuticals, Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Telomir Pharmaceuticals,'s multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
MDCX  4.47 (0.68) 0.00 (0.85) 0.00 
 0.00 
 7.39 
(8.93)
 23.54 
GNTA  5.98 (0.19) 0.00  0.21  0.00 
 0.00 
 6.96 
(11.06)
 138.40 
IPSC  3.68  1.12  0.22  0.80  4.16 
(4.79)
 9.80 
(5.08)
 27.66 
BRNS  4.42 (0.74) 0.00 (0.45) 0.00 
 0.00 
 8.45 
(9.85)
 39.07 
CVM  3.93 (0.79) 0.00  8.86  0.00 
 0.00 
 6.31 
(10.73)
 25.92 
KPTI  3.44  0.17  0.05  0.18  3.90 
(3.54)
 8.24 
(5.76)
 16.03 
SKYE  5.69 (1.73) 0.00 (0.87) 0.00 
 0.00 
 9.91 
(10.92)
 74.17 
COEP  3.02 (0.16) 0.00 (0.11) 0.00 
 0.00 
 5.91 
(5.66)
 22.14 
EQ  5.66  0.12  0.03  0.11  5.49 
(8.74)
 18.89 
(11.76)
 35.57 
INMB  3.37 (0.33) 0.00 (0.09) 0.00 
 0.00 
 6.81 
(6.07)
 18.32 
All Fundamental Data

Telomir Pharmaceuticals, Competitive Analysis

The better you understand Telomir Pharmaceuticals, competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Telomir Pharmaceuticals,'s competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Telomir Pharmaceuticals,'s competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
TELO MDCX GNTA IPSC BRNS CVM KPTI SKYE COEP EQ
 2.10 
 1.40 
Telomir
 2.56 
 1.52 
Medicus
 2.04 
 1.50 
Genenta
 13.95 
 0.98 
Century
 1.39 
 0.71 
Barinthus
 2.20 
 4.44 
CEL
 2.34 
 7.44 
Karyopharm
 7.61 
 0.85 
Skye
 2.61 
 14.92 
Coeptis
 3.57 
 1.35 
Equillium
Market Volatility
(90 Days Market Risk)
Unstable
Dangerous
Extremely Dangerous
Dangerous
Dangerous
Somewhat reliable
Slightly risky
Out of control
Relatively risky
Extremely Dangerous
Market Performance
(90 Days Performance)
Weak
Weakest
Weakest
Solid
Weakest
Weakest
Soft
Weakest
Weakest
Weak
Odds of Financial Distress
(Probability Of Bankruptcy)
High
Average
High
High
Risky
Risky
Strong
Small
Low
Small
Current Valuation
(Equity Enterprise Value)
Under Valued
Fairly Valued
Under Valued
Under Valued
Under Valued
Under Valued
Under Valued
Over Valued
Over Valued
Under Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Strong Buy
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Strong Sell
Strong Sell
Strong Sell
Hold
Strong Sell
Strong Sell
Cautious Hold
Strong Sell
Cautious Hold
Strong Sell
Current Ratio
N/A
0.53
34.15
17.79
N/A
7.71
3.88
0.91
0.56
3.98
Net Asset
1.32 M
5.65 M
14.82 M
353.22 M
160.33 M
26.99 M
164.42 M
72.76 M
8.91 M
25.6 M
Profit Margin
N/A
N/A
N/A
-0.23
N/A
N/A
-0.87
N/A
N/A
N/A
EBITDA
48 K
(323.24 K)
(9.72 M)
(111.47 M)
(55.37 M)
(22.21 M)
(38.6 M)
(25.29 M)
(9.44 M)
(7.57 M)
Current Valuation
49.26 M
33.27 M
22.61 M
(12.72 M)
(33.3 M)
47.42 M
267.53 M
(5.5 M)
76.76 M
37.65 M
Price To Book
7.04
15.81
2.43
0.43
0.35
5.59
12.05
0.9
7.89
2.26
Operating Margin
N/A
N/A
N/A
-0.2
N/A
N/A
-0.35
N/A
-22.53
-5.55
Retained Earnings
(30.6 M)
(28.9 M)
(56.06 M)
(782.34 M)
(237.66 M)
(514.01 M)
(1.56 B)
(130.95 M)
(98.23 M)
(193.81 M)
Current Asset
N/A
N/A
N/A
N/A
N/A
5.89 M
130.25 M
N/A
N/A
60.04 M
Beta
N/A
-1.98
0.57
1.81
-0.66
0.51
0.23
2.68
-0.5
1.92
Number Of Employees
7
10
13
140
105
10
279
16
5
35
Shares Outstanding
34.38 M
24.71 M
23.43 M
87.41 M
40.83 M
7.99 M
17.05 M
32.06 M
4.82 M
60.89 M
Cash Flow From Operations
(5.07 M)
(10.25 M)
(6.24 M)
(110.14 M)
(28.94 M)
(18.81 M)
(127.49 M)
(25.24 M)
(6.65 M)
(19.03 M)
Total Debt
93.43 K
2.51 M
14.6 K
53.83 M
12.01 M
11.62 M
194.52 M
455.59 K
1.4 M
384 K
Return On Equity
-3.03
-26.61
-0.6
-0.14
-0.62
-3.28
-8.91
-0.94
-3.72
-0.9
Return On Asset
-1.67
-1.71
-0.27
-0.0447
-0.23
-0.7
-0.46
-0.55
-0.98
-0.44
Number Of Shares Shorted
2.47 M
493.43 K
168.47 K
608.27 K
9.09 K
526.58 K
341.39 K
1.06 M
160.98 K
770.14 K
Book Value Per Share
0.21
-0.043
0.74
2.04
2.07
1.32
-30.94
1.06
1.46
0.51
Current Liabilities
N/A
N/A
N/A
N/A
N/A
4.01 M
14.95 M
N/A
N/A
1.81 M
Total Asset
1.32 M
5.65 M
14.82 M
353.22 M
160.33 M
26.99 M
164.42 M
72.76 M
8.91 M
25.6 M
Short Ratio
3.74
1.9
0.22
0.44
0.07
5.3
3.09
3.66
1.67
1.76
Target Price
15.5
20.03
7.02
3.0
5.5
42.5
14.67
8.25
3.0
2.5
Debt To Equity
N/A
N/A
N/A
0.12
N/A
0.41
2.59
0.84
1.89
0.29
Shares Owned By Institutions
6.81
13.89
10.03
38.59
44.01
10.7
32.67
62.91
3.9
45.87
Market Capitalization
49.16 M
38.55 M
34.45 M
85.6 M
29.4 M
53.14 M
123.96 M
29.49 M
68.21 M
85.25 M
Price To Earning
N/A
-0.21
N/A
86.08
N/A
-1.14
-3.9
N/A
N/A
-6.7
Price To Earnings To Growth
N/A
N/A
N/A
0.26
N/A
N/A
-0.15
N/A
N/A
N/A
Price To Sales
N/A
N/A
N/A
0.76
3.25
11797.42
0.87
N/A
163.3
19.41
Net Income
(16.53 M)
(11.16 M)
(8.91 M)
(126.57 M)
(61.18 M)
(26.92 M)
(76.42 M)
(26.57 M)
(10.88 M)
(8.07 M)
Earnings Per Share
-0.37
-2.23
-0.55
-0.32
-1.88
-9.13
-15.58
-1.3
-6.87
-0.58
Shares Owned By Insiders
44.98
33.12
37.0
26.09
13.37
8.2
6.59
1.39
13.39
21.06
Revenue
N/A
N/A
N/A
6.59 M
14.97 M
N/A
145.24 M
N/A
N/A
41.09 M
Working Capital
643.04 K
3.07 M
12.37 M
64.27 M
110.08 M
1.44 M
64.23 M
66.49 M
(3.46 M)
18.62 M
Cash And Equivalents
N/A
1.22 K
37.24 M
378.76 M
N/A
4.74 M
170.85 M
2.93 M
2.38 M
57.56 M
Cash Per Share
N/A
N/A
2.04
6.43
N/A
0.65
2.14
0.01
0.06
1.68
Gross Profit
N/A
N/A
N/A
7.99 M
10.52 M
(16.66 M)
148.71 M
N/A
173.24 K
4.39 M
Day Typical Price
1.41
1.54
1.54
0.93
0.71
4.48
7.38
0.88
14.91
1.44
Accumulation Distribution
0.0347
0.0745
0.14
0.2
0.0811
0.1
0.0543
0.12
0.0323
0.19
Market Facilitation Index
0.05
0.12
0.23
0.2
0.06
0.49
0.41
0.11
0.49
0.31
Daily Balance Of Power
(0.60)
(0.33)
0.1304
0.6
(0.17)
(0.20)
0.4146
(0.64)
(0.82)
(0.16)
Period Momentum Indicator
(0.03)
(0.04)
0.03
0.12
(0.01)
(0.10)
0.17
(0.07)
(0.40)
(0.05)
Rate Of Daily Change
0.98
0.97
1.02
1.14
0.99
0.98
1.02
0.92
0.97
0.96
Day Median Price
1.42
1.55
1.57
0.9
0.71
4.5
7.35
0.9
14.91
1.49
Price Action Indicator
(0.03)
(0.05)
(0.05)
0.14
(0.01)
(0.10)
0.18
(0.08)
(0.19)
(0.16)
Coefficient Of Variation
3715.81
(872.92)
(5,608)
429.73
(973.82)
(661.52)
1600.27
(592.08)
(4,096)
3229.89
Mean Deviation
3.77
4.47
5.98
3.68
4.42
3.93
3.44
5.69
3.02
5.66
Jensen Alpha
0.1309
(0.68)
(0.19)
1.12
(0.74)
(0.79)
0.169
(1.73)
(0.16)
0.1164
Total Risk Alpha
(0.33)
(1.09)
(1.47)
0.7751
(1.18)
(1.22)
(0.1)
(2.42)
(0.44)
(0.44)
Sortino Ratio
0.0163
N/A
N/A
0.2152
N/A
N/A
0.0482
N/A
N/A
0.0307
Downside Variance
27.66
N/A
N/A
28.73
N/A
N/A
16.02
N/A
N/A
36.69
Standard Deviation
5.73
5.47
14.51
5.25
6.32
5.17
4.18
9.54
3.98
8.21
Kurtosis
7.57
(0.47)
27.59
3.47
3.58
0.3417
(0.50)
22.22
0.6465
2.05
Potential Upside
5.73
7.39
6.96
9.8
8.45
6.31
8.24
9.91
5.91
18.89
Treynor Ratio
0.6287
(0.85)
0.2106
0.8023
(0.45)
8.86
0.1783
(0.87)
(0.11)
0.1115
Maximum Drawdown
41.27
23.54
138.4
27.66
39.07
25.92
16.03
74.17
22.14
35.57
Variance
32.86
29.95
210.4
27.56
39.9
26.74
17.45
91.1
15.87
67.33
Market Risk Adjusted Performance
0.6387
(0.84)
0.2206
0.8123
(0.44)
8.87
0.1883
(0.86)
(0.10)
0.1215
Risk Adjusted Performance
0.0277
(0.07)
(0)
0.1719
(0.06)
(0.1)
0.0522
(0.11)
(0.01)
0.0309
Skewness
1.56
0.2964
3.63
0.1891
0.7021
(0.41)
0.2966
(3.64)
0.3376
1.31
Semi Deviation
4.67
N/A
N/A
4.16
N/A
N/A
3.9
N/A
N/A
5.49
Information Ratio
0.015
(0.13)
(0.02)
0.2197
(0.11)
(0.16)
0.0461
(0.18)
(0.04)
0.0226
Value At Risk
(8.00)
(8.93)
(11.06)
(5.08)
(9.85)
(10.73)
(5.76)
(10.92)
(5.66)
(11.76)
Expected Short fall
(4.32)
N/A
N/A
(4.79)
N/A
N/A
(3.54)
N/A
N/A
(8.74)
Downside Deviation
5.26
N/A
N/A
5.36
N/A
N/A
4.0
N/A
N/A
6.06
Semi Variance
21.81
N/A
N/A
17.27
N/A
N/A
15.2
N/A
N/A
30.16

Telomir Pharmaceuticals, Competition Performance Charts

Five steps to successful analysis of Telomir Pharmaceuticals, Competition

Telomir Pharmaceuticals,'s competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Telomir Pharmaceuticals, in relation to its competition. Telomir Pharmaceuticals,'s competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Telomir Pharmaceuticals, in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Telomir Pharmaceuticals,'s competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Telomir Pharmaceuticals,, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Telomir Pharmaceuticals, position

In addition to having Telomir Pharmaceuticals, in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Alternative Energy Thematic Idea Now

Alternative Energy
Alternative Energy Theme
Large and mid-size companies, ETFs and funds that are either investing or directly involved in providing energy derived from sources not connected to fossil fuels, do not consume natural resources, and do not harm the environment. This includes wind power, nuclear and solar energy, biofuel, ethanol, hydrogen and others alternative sources of energy. The Alternative Energy theme has 28 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Alternative Energy Theme or any other thematic opportunities.
View All  Next Launch
When determining whether Telomir Pharmaceuticals, offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Telomir Pharmaceuticals,'s financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Telomir Pharmaceuticals, Common Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Telomir Pharmaceuticals, Common Stock:
How To Invest In Telomir
Details
Is Telomir Stock a good investment?
Details
What is Telomir Pharmaceuticals,'s Net Worth?
Details
Largest Pharmaceuticals Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out Telomir Pharmaceuticals, Correlation with its peers.
You can also try the USA ETFs module to find actively traded Exchange Traded Funds (ETF) in USA.
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Telomir Pharmaceuticals,. If investors know Telomir will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Telomir Pharmaceuticals, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Telomir Pharmaceuticals, is measured differently than its book value, which is the value of Telomir that is recorded on the company's balance sheet. Investors also form their own opinion of Telomir Pharmaceuticals,'s value that differs from its market value or its book value, called intrinsic value, which is Telomir Pharmaceuticals,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Telomir Pharmaceuticals,'s market value can be influenced by many factors that don't directly affect Telomir Pharmaceuticals,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Technical
Analysis
Details
Please note, there is a significant difference between Telomir Pharmaceuticals,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Telomir Pharmaceuticals, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Telomir Pharmaceuticals,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2025 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY